Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced updated data from the global Phase 1 clinical trial of ...

The issue of attendance has become a focus for the district, which has been included in a pilot program with 11 other ...

Nektar Therapeutics (NASDAQ:NKTR) is one of the hot stocks to buy with huge upside potential. On October 22, Nektar ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the presentation of multiple abstracts demonstrating the clinical benefits of treatment with CFTR modulators, including the Company’s ...

VYVGART demonstrated clinically meaningful benefit across all AChR-Ab seronegative gMG subtypes in ADAPT SERON, supporting broad role of ...

As of July 31, 2025, the objective response rate (ORR) was 90% in NTRK fusion patients, as assessed by the Independent Review Committee (IRC). Among the patients who completed full efficacy ...

New safety, efficacy and pharmacokinetic results presented from dose escalation portion of the study Anti-tumour activity observed across all dose levels and in various tumour indications  Newcastle, ...

Bio shares rose sharply after announcing upcoming presentations on its obesity treatment candidate at two industry ...

Mallinckrodt plc, a global specialty pharmaceutical company, today announced the presentation of four posters in patients with hepatorenal syndrome (HRS), including a Poster of Distinction, at The ...

SystImmune & Bristol Myers Squibb announce first global phase I results of iza-bren, an EGFR x HER3 bispecific ADC, in patients with advanced solid tumours at ESMO 2025 ...

Light Chain Bioscience, a clinical-stage biotechnology company advancing the next generation of bispecific antibodies to treat cancer, today presented positive results from a Phase 1/1b study of ...

Nektar Therapeutics (Nasdaq: NKTR) announced today that new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin ...